PNC Financial Services Group Inc. lifted its position in Qiagen NV (NASDAQ:QGEN) by 54.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 209,223 shares of the company’s stock after purchasing an additional 74,190 shares during the quarter. PNC Financial Services Group Inc. owned approximately 0.09% of Qiagen worth $7,926,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Parallel Advisors LLC raised its stake in Qiagen by 548.5% during the 3rd quarter. Parallel Advisors LLC now owns 3,210 shares of the company’s stock valued at $122,000 after acquiring an additional 2,715 shares during the last quarter. Prudential Financial Inc. purchased a new stake in Qiagen during the 3rd quarter valued at approximately $206,000. Private Trust Co. NA purchased a new stake in Qiagen during the 3rd quarter valued at approximately $233,000. Lourd Capital LLC purchased a new stake in Qiagen during the 3rd quarter valued at approximately $250,000. Finally, Acorn Advisory Capital L.P. purchased a new stake in Qiagen during the 3rd quarter valued at approximately $364,000. 62.23% of the stock is owned by hedge funds and other institutional investors.
Several analysts have commented on the company. BidaskClub raised Qiagen from a “sell” rating to a “hold” rating in a research note on Wednesday, August 29th. Commerzbank reaffirmed a “buy” rating on shares of Qiagen in a research note on Wednesday, August 29th. Barclays reaffirmed a “buy” rating and set a $43.00 price objective on shares of Qiagen in a research note on Thursday, September 6th. Deutsche Bank set a $44.00 price objective on Qiagen and gave the company a “buy” rating in a research note on Friday, October 5th. Finally, Morgan Stanley upped their price objective on Qiagen from $39.00 to $41.00 and gave the company an “overweight” rating in a research note on Wednesday, October 31st. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Qiagen currently has an average rating of “Hold” and an average target price of $39.13.
Qiagen (NASDAQ:QGEN) last issued its earnings results on Monday, October 29th. The company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.02. The business had revenue of $377.90 million for the quarter, compared to analysts’ expectations of $380.11 million. The business’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the company posted $0.32 earnings per share.
ILLEGAL ACTIVITY NOTICE: “Qiagen NV (QGEN) Shares Bought by PNC Financial Services Group Inc.” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/12/02/qiagen-nv-qgen-shares-bought-by-pnc-financial-services-group-inc.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Further Reading: What is an SEC Filing?
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NASDAQ:QGEN).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.